“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”
Open Access
- 10 September 2022
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (2) , e58-e69
Abstract
No abstract availableKeywords
Funding Information
- Bayer
This publication has 30 references indexed in Scilit:
- Managing Nonmetastatic Castration-resistant Prostate CancerEuropean Urology, 2019
- Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2018
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2018
- Apalutamide Treatment and Metastasis-free Survival in Prostate CancerNew England Journal of Medicine, 2018
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Journal of Clinical Oncology, 2016
- Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelPLOS ONE, 2015
- Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice GuidelineJournal of Clinical Oncology, 2014
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling TimeJournal of Clinical Oncology, 2013
- Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancerCancer, 2010
- Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate CancerJournal of Clinical Oncology, 2005